Sign in
Taking people in United StatesNo phase

Studies how drugs given to children with several conditions act in the body

Measures how standard drugs act in children and young adults receiving them.

Key facts

Who runs it
Duke University
Where
Albuquerque, Aurora, Austin, Baltimore, Boston, Chapel Hill, Charleston, Chicago, Cincinnati, Columbia, Dallas, Durham, Hershey, Honolulu, Houston, Indianapolis, Iowa City, Jackson, Jacksonville, Kansas City, Lebanon, Lexington, Little Rock, Los Angeles, Louisville, Madison, Milwaukee, Minneapolis, Morgantown, Nashville, New Orleans, Oklahoma City, Omaha, Palo Alto, Phoenix, Portland, Providence, Salt Lake City, Seattle, Sioux Falls, and Wilmington, United StatesSee the 48 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Status
Recruiting
People taking part
5,000 people, planned
Started
5 Mar 2020
Expected to end
Dec 2026
Type of study
Observational
Treatments tested
  • The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Record updated
21 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults under 21 who are getting certain medicines from their doctor as usual care, or who recently tested positive for SARS-COV-2. It studies how the medicines act in the body.

Age
Under 21 years (0 to 20 years).
Sex
All sexes can join.
Earlier treatment
Taking one or more of the study drugs at enrollment, or a positive SARS-COV-2 test within 60 days before enrollment.
Biomarker or test result
A positive SARS-COV-2 test within 60 days is accepted for people not taking the study drugs.

Main reasons for not taking part

  • Known pregnancy
  • Dialysis (intermittent) within the previous 24 hours
  • Kidney transplant within the previous 30 days
  • Liver or stem cell transplant within the previous 1 year
  • Ventricular assist device

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Participant is < 21 years of age
  • Parent/ Legal Guardian/ Adult Participant can understand the consent process and is willing to provide informed consent/HIPAA:
  • (a) Participant is receiving one or more of the study drugs of interest at the time of enrollment or (b) Participant is NOT receiving one or more of the study drugs of interest but is SARS-COV-2 positive within 60 days prior to enrollment

Who cannot take part

  • Participant has a known pregnancy; Below exclusion criteria apply only to:; Participants receiving one or more of the study drugs of interest at the time of enrollment, DOI administration or PK sampling: (Refer to DOI specific appendices for details on enrollment cohort specifications and additional eligibility criteria)
  • Has had intermittent dialysis within previous 24 hours
  • Has had a kidney transplant within previous 30 days
  • Has had a liver transplant within previous 1 year
  • Has had a stem cell transplant within previous 1 year
  • Has had therapeutic hypothermia within previous 24 hours
  • Has had plasmapheresis within the previous 24 hours
  • Has any condition which would make the participant, in the opinion of the investigator, unsuitable for the study
  • Has a Ventricular Assist Device

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 0 and 20 years old?

Where in United States

Also in 1 other country, 2 sites

  • University of New Mexico Health Science CenterAlbuquerque, United StatesContact: Chi HornikNo longer taking part
  • Colorado University DenverAurora, United StatesContact: Chi HornikNo longer taking part
  • The Children's Hospital ColoradoAurora, United StatesContact: Chi HornikNo longer taking part
  • Dell Children's Medical Center of Central TexasAustin, United StatesContact: Michael BoxTaking people
  • University of Maryland Medical CenterBaltimore, United StatesContact: Chi HornikNo longer taking part
  • Boston Children's HospitalBoston, United StatesContact: Chi HornikNo longer taking part
  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Chi HornikNo longer taking part
  • Medical University of South Carolina Children's HospitalCharleston, United StatesContact: Chi HornikNo longer taking part
  • Ann and Robert H Lurie Childrens Hospital of ChicagoChicago, United StatesContact: Chi HornikNo longer taking part
  • Cincinnati Childrens Hospital Medical CenterCincinnati, United StatesContact: Chi HornikNo longer taking part
  • University of South CarolinaColumbia, United StatesContact: Chi HornikNo longer taking part
  • University of Texas Southwestern Medical Center - DallasDallas, United StatesContact: Chi HornikNo longer taking part
  • Duke University Health SystemDurham, United StatesContact: Melissa HarwardTaking people
  • Pennsylvania State University--Hershey Children's HospitalHershey, United StatesContact: Chi HornikNo longer taking part
  • Kapiolani Womens and Childrens Medical CenterHonolulu, United StatesContact: Chi HornikNo longer taking part
  • Baylor College of MedicineHouston, United StatesContact: Chi HornikNo longer taking part
  • The Womens Hospital of TexasHouston, United StatesContact: Chi HornikNo longer taking part
  • University of Texas--Memorial Hermann Texas Medical CenterHouston, United StatesContact: Chi HornikNo longer taking part
  • Riley Hospital for Children at Indiana UniversityIndianapolis, United StatesContact: Chi HornikNo longer taking part
  • University of Iowa Stead Family Children's HospitalIowa City, United StatesContact: Chi HornikNo longer taking part
  • University of Mississippi Medical CenterJackson, United StatesContact: Chi HornikNo longer taking part
  • University of Florida Jacksonville Shands Medical CenterJacksonville, United StatesContact: Chi HornikNo longer taking part
  • Children's Mercy HospitalKansas City, United StatesContact: Chi HornikNo longer taking part
  • University of Kansas Medical Center-JG Kidney InstituteKansas City, United StatesContact: Chi HornikNo longer taking part
  • Dartmouth Hitchcock Medical CenterLebanon, United StatesContact: Chi HornikNo longer taking part
  • Massachusetts General HospitalLexington, United StatesContact: Chi HornikNo longer taking part
  • Arkansas Children's Hospital Research InstituteLittle Rock, United StatesContact: Chi HornikNo longer taking part
  • University of California Los Angeles Medical CenterLos Angeles, United StatesContact: Chi HornikNo longer taking part
  • University of Louisville Norton Childrens HospitalLouisville, United StatesContact: Chi HornikNo longer taking part
  • Mississippi Center for Advanced MedicineMadison, United StatesContact: Chi HornikNo longer taking part
  • University of WisconsinMadison, United StatesContact: Chi HornikNo longer taking part
  • University Wisconsin MadisonMadison, United StatesContact: Chi HornikNo longer taking part
  • Medical College of WisconsinMilwaukee, United StatesContact: Chi HornikNo longer taking part
  • University of MinnesotaMinneapolis, United StatesContact: Chi HornikNo longer taking part
  • West Virginia University HospitalMorgantown, United StatesContact: Chi HornikNo longer taking part
  • Monroe Carell Jr. Children's Hospital at VanderbiltNashville, United StatesContact: Chi HornikNo longer taking part
  • Ochsner Baptist Clinical Trials UnitNew Orleans, United StatesContact: Chi HornikNo longer taking part
  • Tulane University Health Science CenterNew Orleans, United StatesContact: Chi HornikNo longer taking part
  • Board of Regents of the University of OklahomaOklahoma City, United StatesContact: Chi HornikNo longer taking part
  • University of Nebraska Medical CenterOmaha, United StatesContact: Chi HornikNo longer taking part
  • Lucile Packard Children's HospitalPalo Alto, United StatesContact: Yasaman NourkhalaTaking people
  • Phoenix Children s HospitalPhoenix, United StatesContact: Chi HornikNo longer taking part
  • Oregon Health and Science UniversityPortland, United StatesContact: Chi HornikNo longer taking part
  • Rhode Island HospitalProvidence, United StatesContact: Chi HornikNo longer taking part
  • University of UtahSalt Lake City, United StatesContact: Chi HornikNo longer taking part
  • Seattle Children's HospitalSeattle, United StatesContact: Chi HornikNo longer taking part
  • Avera McKennan Hospital & University Medical CenterSioux Falls, United StatesContact: Chi HornikNo longer taking part
  • Alfred I duPont Hospital for ChildrenWilmington, United StatesContact: Chi HornikNo longer taking part

About the trial

What the trial wants to find out

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

The group in the trial

  • Children and young adults who are prescribed drugs of interest

    Children and young adults who are prescribed drugs of interest as part of their routine medical care OR are SARS-CoV-2 positive.

    Treatment: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs
Plain-language title
Studies how drugs given to children with several conditions act in the bodyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04278404, who can take part
Record updated
21 August 2026